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Introduction: COSTOP was a randomised controlled trial designed to assess the risks and beneﬁts to HIV-
infected participants stabilised on anti-retroviral treatment of stopping cotrimoxazole (CTX). In order to
assess the extent to which patients may have had access to and used CTX other than that supplied as
study drug it was decided to conduct an exit interview.
Methods: A structured interview was administered by interviewers who were not associated with the
COSTOP trial team in order to make it easier for participants to respond truthfully to sensitive questions
about adherence to the study protocol.
Results: A total of 1993 participants were interviewed. Only 29 (1.7%) said they had taken their left over
CTX; 101 (6.1%) had kept supplies at home. When asked about obtaining open label CTX during the trial
92 (4.7%) participants said they had done so, in contrast to only 12 who admitted doing so when asked at
trial visits. The questions participants found most difﬁcult to answer honestly at clinic visits were those
concerning adherence to trial drugs (15.6% of participants) and whether they had slept under the
insecticide treated mosquito nets (14.9%).
Discussion: The exit interview demonstrated that there was some evidence of open label drug being
taken by the participants. However, the results from the interview do not suggest that the trial results
would have been seriously compromised. We would recommend the exit interview as a valuable way of
assessing adherence to trial procedures.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Background
Cotrimoxazole (CTX) is widely used as prophylaxis against
opportunistic infections among HIV-infected persons as recom-
mended by the World Health Organisation [1]. The beneﬁts of
continuing to use CTX in patients in limited resource settings who
have been stabilised on antiretroviral treatment are unknown.
COSTOP was a double blind placebo controlled trial designed to
evaluate the beneﬁts and risks associated with stopping CTX in two
sites in Uganda [2].
For intervention trials, like COSTOP, that include providereclient
interactions, exit interviews with clients are recommended to
monitor their understanding of the advice that was provided [3].
Laboratory based tests to detect the treatment under study are
often non-existent or expensive, and therefore exit interviews
conducted by independent research staff are an important way in
which to evaluate adherence to study product [4] Findings from
exit interviews have been reported in brief inmany accounts of trial
ﬁndings but the experience of using this technique has only occa-
sionally been presented in standalone papers [5,6].
Because most patients entering the COSTOP would be expected
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to have unused supplies of CTX at home and the drug is relatively
inexpensive and can readily be obtained over the counter in
Uganda the investigators considered it important to assess the
extent to which patients might have taken left over supplies or
drugs from other sources while participating in the trial. Use of CTX
outside of the study clinics could potentially render the results of
the trial uninterpretable. A simple test to identify metabolites of
CTX in randomly collected urine samples would have been the best
way to identify patients allocated to placebo who were taking
active drug and to assess whether those allocated to active drug
were taking it. Unfortunately no such test is available and although
participants were asked at each visit whether they been taking
open-label CTX it would have been difﬁcult for them to admit to the
study team that they had not followed protocol instructions.
In order to assess the extent to which patients may have had
access to and used CTX other than that supplied as study drug it
was decided to conduct an exit interview to be administered to all
participants by persons not directly associated with the COSTOP
trial team in order to make it easier for the participants to respond
truthfully to sensitive questions. The present paper reports on the
conduct of the exit interview, the ﬁndings and the implications for
the interpretation of the main trial results.
Only very few clinical trials provide a detailed report on the use
and the results of exit interviews to measure adherence in placebo
controlled studies. Our paper therefore also provides a contribution
to clinical trial methodology.
2. Methods
The methods of the main COSTOP study (trial registration
number: ISRCTN44723643) have already been reported in detail
[2]. In brief, COSTOP was a randomised double blind placebo
controlled non-inferiority trial conducted in two clinics in Entebbe
and Masaka in Uganda. The study aims were to assess whether
stopping CTX is not inferior to continuing with respect to the
incidence of pre-deﬁned CTX-preventable events and superior with
respect to the reduced incidence of haematological adverse events.
Eligible patients were adults aged 18 years or more, infected with
HIV who had been receiving antiretroviral treatment (ART) for at
least sixmonths, whowere clinically asymptomatic having had two
CD4 counts (not more than 6months apart) of250 cells/mm3, the
most recent no more than 4 weeks prior to enrolment. Participants
were instructed to stop taking their regular supplies of CTX after
which they were randomised in equal proportions to receive either
CTX provided by the study or a matching placebo; all continued to
receive ART as prescribed. Participants were provided with an
insecticide treated mosquito net (ITN) and educated about the
importance of using it. They were told that both they the study
team were blinded to the treatment assignment and that it was
important that they did not acquire CTX from any other source.
Participants were told to present their COSTOP study appointment
cards at the ART service points, private clinics or public health
centres and to inform the staff not to prescribe or dispense CTX to
them. They were seen monthly for the ﬁrst three months and every
three months thereafter for a minimum follow-up of one year post-
randomisation. At each visit patients were seen by a study nurse
and trial physician for protocol related assessments. A question-
naire to document adherence to ART and trial drug was adminis-
tered on each occasion which included a question on whether
participants had had access to open label CTX. The trial had 80%
power to detect non-inferiority of placebo to CTX with respect to
cotrimoxazole preventable events i.e. the upper limit of the one-
sided 95% conﬁdence interval of the hazard ratio (HR) for placebo
relative to CTX should be no greater than 1.25 (a relative increase of
25%). A total of 2000 participants were required to be enrolled.
The trial was closed after the last randomised patient had
completed one year in the study. At the ﬁnal study visit all patients
were requested to participate in an exit interview. They were
randomised to be interviewed either by a ﬁeld worker from the
Social Science programme of the MRC/UVRI Uganda Research Unit
or by a trained peer interviewer from TASO (The AIDS Support
Organisation) in Entebbe or Kampala. A total of eight interviewers
(four social scientists and four peers) conducted the interviews
using a questionnaire with pre-deﬁned options for answers tomost
of the questions (see Appendix for details).
3. Results
The results of the main study have been presented [7]. In brief
they showed that among HIV-infected adults on ART with a CD4
count above 250 cells/mm3, discontinuing CTX signiﬁcantly
increased the risk of CTX preventable bacterial infections (partic-
ularly pneumonia), and of malaria and led to an increase in hospital
admission rates. However, discontinuing CTX also signiﬁcantly
reduced the risk of laboratory determined grade three or four
haematological adverse events, in particular neutropenia. The trial
found no evidence that discontinuing CTX led to an increase in
mortality.
Of 2180 participants enrolled into the trial 37 died before the
ﬁnal visit, 95 were lost to follow-up, 49 hadwithdrawn consent and
six were not interviewed at their ﬁnal study visit. A total of 1993
remained (1001 allocated to CTX, 992 allocated to placebo) with
whom the exit interviewwas conducted, in 1007 instances by social
scientists and 986 by peer interviewers.
The majority of participants, 1667 (83.6%) of 1993, reported that
they had supplies of CTX left over at the time they joined the study;
283 (14.2%) said they had none and 43 (2.2%) said they could not
recall what they had. Of those with supplies left over at the
beginning of the study the majority either submitted them to the
study clinic or to their ART provider (Table 1); 101 (6.1%) kept them
at home and 29 (1.7%) took them either before or at the same time
as taking the study drug. Therewereminor differences according to
the allocated treatment arm and who interviewed the participants.
Participants were asked how often they reported having taken
the trial drug when they had actually missed some doses; 144
(7.2%) of them admitted to doing so regularly and a further 325
(16.3%) occasionally. In the course of discussions with other par-
ticipants 430 (21.6%) reported that they were aware that others had
found it difﬁcult to admit that they had failed to take the trial drug.
There were no differences between those receiving CTX or placebo.
Of 1963 participants whowere not switched by clinic study staff
to open-label CTX at some time during the trial, 92 (4.7%) admitted
to having had access to the drug from other sources, half of them on
a frequent basis. There was a slight excess among those prescribed
placebo, 50 (5.1%) of 973 compared to 42 (4.2%) of 990 prescribed
CTX. The commonest reported source of CTX from outside the study
Table 1
Response to question “What did you do with the left over cotrimoxazole at trial
entry?”.
No. %
Took to study clinic 705 42.3
Took to ART provider 270 16.2
Gave away 275 16.5
Thrown away 213 12.8
Kept at home 101 6.1
Forgotten 70 4.2
Took before or with trial drug 29 1.7
Other 4 0.2
Total with cotrimoxazole left over 1667 100.0
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clinic was from HIV treatment providers 48 (53.9%) followed by
pharmacies 35 (39.3%). The reasons for obtaining CTX are given in
Table 2; the commonest reason being for the treatment or pre-
vention of opportunistic infections. In a small proportion of par-
ticipants, 12.5% of the 88 who gave a reason, it was on account of
having ﬁnished tablets provided by the study clinic. These partici-
pants were usually travelling and unable to attend for their regular
appointment.
In these responses, we observed some substantial differences
between participants according to their allocated trial arm. For
example, the proportion of patients reporting to have taken open
label CTX because they had run out of study drug was about twice
as high in the CTX group than in the placebo group (17.9% vs. 8.2%),
and those who did so to treat an infection or fever was also higher
in the CTX arm (53.8% vs. 38.8%). Responses differed also substan-
tially by category of interviewer: for example, among participants
interviewed by a peer, about 61.0% stated that they took additional
CTX to treat an infection or fever, whilst only 31.9% of those inter-
viewed by a social scientist gave this reason.
Participants were asked which questions they found difﬁcult to
answer honestly at clinic visits, the results are shown in Table 3.
Being asked about missed trial drugs was the commonest of these
questions followed by whether or not they had slept under ITNs.
There was a notably higher level of admission to problems when
giving an answer to the questions about trial drug and missed ART
doses when the social scientists were the interviewers, P < 0.001
for both comparisons. The differences by allocated treatment arm
were small.
Among other questions addressed to the participants was the
frequency of taking the trial drug compared to how often they took
CTX before entering the trial (data not tabulated). Responses were
evenly split between those saying they took the trial drug more
frequently (45.8%) or with the same frequency (43.9%), the
remaining 10.3% reported that they took the trial drug less often.
There were only small differences by treatment arm, 46.8% of those
on CTX and 44.7% of those receiving placebo saying that they took
the trial drug more frequently.
A small proportion of participants, 14.3% (13.0% CTX, 15.6% pla-
cebo), said they had attempted at some time to guess what treat-
ment they were receiving. Of the 273 who did guess, a signiﬁcantly
higher proportion of those receiving placebo, 99 (65.1%) of 152,
guessed correctly compared to 53 (43.8%) of 121 receiving CTX
(P < 0.001).
Asked whether a potential trial outcome showing that stopping
CTX was safe would mean they would still want to continue to take
it, 471 (23.6%) said it was very likely they would want to do so and
46 (2.3%) said it was somewhat likely. However, the majority of
patients, 1464 (73.5%) said they would encourage their friends to
discontinue taking it if stopping were found to be safe.
4. Discussion
The purpose in conducting an exit interview at the conclusion of
the COSTOP trial was to attempt to determine the extent to which
the outcome of the trial may have been inﬂuenced by failure to
adhere to the study protocol, resulting in a dilution of differences in
the primary outcome between the allocated treatment arms. If
more than a small proportion of participants had had access to
sources of CTX outside the conﬁnes of the study clinics there would
have been a serious risk of wrongly declaring the placebo arm to be
non-inferior to the CTX arm with respect to the proportion of
participants experiencing a CTX preventable event. The exit survey
revealed, not unexpectedly, that there were a number of questions
related to protocol adherence that participants found difﬁcult to
answer honestly at routine study visits. The commonest of these
related to missed study drug and use of insecticide treated mos-
quito nets.
We cannot be sure that the responses given in the exit interview
were always truthful. However, the interviews were administered
by persons who had had no previous contact with the participants
and were not linked to the trial. It is reasonable therefore to assume
that participants were more likely to have been honest at these exit
interviews; and it is clear from the answers to a number of the
questions that participants were prepared to admit to behaviour
they had not admitted to trial staff during the trial. In conducting an
exit interview of this kind considerable care needs to be attached to
the framing of the questions, the training of those administering
the questionnaire and assurance given to the study participants
that there will be no sanctions imposed for admitting failure to
comply with study procedures.
CTX is readily available over the counter in Uganda and in
addition most participants would have had supplies at home at the
time of entering the COSTOP trial. It is reassuring to note that the
proportion of participants admitting to having taken either some of
the drug they had left over at home (1.7%) or having obtained drug
from other sources during the trial (4.7%) is relatively small
although 46 patients (2.3%) admitted to having done so frequently.
Of the 92 participants who admitted at exit interview they had had
access to CTX during the trial, only 12 had replied in the afﬁrmative
when asked during the trial by trial staff about whether they had
taken any open label CTX since their previous clinic visit. A reluc-
tance to mention non-adherence while the trial was in progress
was corroborated by the ﬁndings of a small qualitative sub-study of
patient perceptions and adherence to allocated treatment which
was conducted in 30 patients (10 who had been allocated to receive
active CTX and 20 who had been allocated to matching placebo)
during the trial. The ﬁndings of this substudy suggested that
adherence to study procedures were generally good and there was
very little by way of evidence to indicate that patients reported
sharing or obtaining drug from other sources. However, while the
team conducting this sub-study was not made up of clinic staff, this
data collectionwas conducted while the trial was in progress at the
clinic site, so it is possible that there may be some social desirability
bias in the responses given. In such a setting it is difﬁcult to know
what else could have been done to limit the possibility of partici-
pants acquiring CTX outside the study clinics.
It is notable from the exit interview ﬁndings that, in the small
number of patients who attempted to guess the treatment they had
been allocated, a signiﬁcantly higher proportion correctly guessed
they were receiving placebo compared with CTX. There was,
however, no evidence to suggest that this seriously inﬂuenced their
Table 2
Response to question “Why did you take open label cotrimoxazole?”.
Why taken? Interviewer Allocated treatment Total
Peer Social
scientist
CTX PLC
N % N % N % N % N %
OI treatment 16 39.0 14 30.0 15 38.5 15 30.6 30 34.1
OI prophylaxis 10 24.4 19 40.4 10 25.6 19 38.8 29 33.0
Fever 9 22.0 1 2.1 6 15.4 4 8.2 10 11.4
Pain/fatigue 4 9.8 5 10.6 3 7.7 6 12.2 9 10.3
Trial drug ﬁnished 4 9.8 7 14.9 7 17.9 4 8.2 11 12.5
Other 1 2.4 1 2.1 1 2.6 1 2.0 2 2.3
Total assessed 41 100.0 47 100.0 39 100.0 49 100.0 88 100.0
OI ¼ opportunistic infection.
No response to question from 4 participants (4 Peer, 1 S Scientist; 3 CTX, 1 PLC).
Three participants (all Peer and CTX) gave more than one reason, 2 pain and fever,
one OI treatment and fever.
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adherence to taking trial drug.
In the comparatively small group of patients who took open
label CTX, we observed striking differences between participants
from different trial arms regarding the reasons for doing so. Inter-
estingly those in the CTX arm reportedmore often than those in the
placebo arm that they took CTX to treat a perceived infection or
fever. Whilst this difference is difﬁcult to understand, it does not
suggest that placebo arm participants found it necessary to take
CTXmore often than those on the active treatment arm. Differences
in responses were also observed depending on the kind of inter-
viewer (peer interviewers vs. trained social science interviewers).
This is of interest from a methodological point of view. It may well
be that these differences were genuine indicating a potential bias
depending on the question: more participants responding honestly
on some topics to a peer and to others when a social scientist was
asking the questions. The potential explanation of the differential
responses will necessarily remain speculative.
For many HIV-positive persons whose infection was diagnosed
before the availability of ART, CTX was one of the few drugs which
provided beneﬁt in the prevention and treatment of opportunistic
infections. At the time of planning the COSTOP trial there was un-
certainty as towhether thosewho had been receiving CTX for many
years would readily agree to the possibility of stopping it. In addi-
tion to providing information on adherence to study procedures the
exit interview obtained the views of the participants as to whether
they would accept the results of the trial if it showed that stopping
CTX was safe. In the event 25.9% indicated that they might wish to
continue using CTX and 73.5% said they would encourage their
friends to discontinue taking it.
The administration of an exit interview questionnaire to this
study population provided valuable information which could not
have been readily obtained through trial follow-up visits. It high-
lighted the fact that there was some evidence of open label drug
being taken by the participants. However, taking the results from
the exit interview as a whole it seems unlikely that the trial results
would have been seriously compromised as a consequence of fail-
ure of participants to always adhere to the study protocol.
It is not unusual to ask patients about their opinion of what
treatment they have been receiving at the close of a double blind
trial although reporting in detail on results from an exit interview is
unusual. In one large placebo controlled trial of over 6000 women
of a microbicide for the prevention of HIV there was a striking
contrast between high rates of self-reported gel use and low pro-
portion of covered sex acts on the basis of an applicator test.
However, a sample of 1602 women were interviewed at the end of
the trial andmany of them admitted they had often failed to use the
gel because they forgot to do so or had run out of supplies [8]. This
ﬁnding was invaluable in understanding the outcome of the trial.
We are aware of very few trials that have published a detailed
analysis of exit interview ﬁndings as that reported here. On the
basis of our ﬁndings we would encourage others to consider using
an exit interview especially when there is uncertainty about the
extent towhich participants are complying with the study protocol.
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